TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03835585

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safety Planning
Description: A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety Planning
Description: A psychological intervention for suicide risk that is based on research (Chu et al., 2015; Stanley \& Brown, 2012). This involves listing the following on an index card: activities individuals can use to feel better during a crisis, contact numbers that are important to the individuals, emergency options that are always accessible, and reasons for living. Although the individualized nature of safety plans does not allow for a scripted/uniform approach, for this study they will all include 8 steps and steps 5-8 (emergency options) will be the same for each individual.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lethal Means Counseling
Description: A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lethal Means Counseling
Description: A psychological intervention for suicide risk that is based on research (Bryan et al., 2011; Chu et al., 2015; Rudd, 2006; Stanley, 2018). This involves a psychological clinician discussing, with an at-risk individual, the importance for increasing the distance/obstacles between the individual at risk for suicide and specific types of lethal means. In the present study, the lethal means targeted was firearms and the lethal means counseling approach was able to be standardized/scripted as has been done in previous research (see Stanley, 2018).
Study: NCT01410409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Burana
Description: 400 mg x 3/day for three weeks
Study: NCT04235270

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FDC of Macitentan and Tadalafil
Description: Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FDC of Macitentan and Tadalafil
Description: Fixed dose combination (FDC) of 1 film-coated tablet containing 10 mg of macitentan and 40 mg of tadalafil will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan 10 mg tablet will be administered orally as free combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan 10 mg tablet will be administered orally as free combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil 40 mg tablet will be administered orally as free combination.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil 40 mg tablet will be administered orally as free combination.
Study: NCT01781403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
Study: NCT01349803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT005 MDI
Description: PT005 MDI administered as two puffs BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT001 MDI
Description: PT001 MDI administered as two puffs BID for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT003 MDI
Description: PT003 MDI administered as two puffs BID for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 μg (Foradil® Aerolizer®)
Description: Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
Study: NCT03921554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Baricitinib will be taken by mouth or via gastrostomy feeding tube or nasogastric tube as directed by the study doctor. Baricitinib will be dosed by patient age, weight range and estimated glomerular filtration rate (eGFR). Dosing formulations in use in this study will include 1 mg and 2 mg tablets and will be used without splitting. Dispersion will be permitted to aid in swallowing.
Study: NCT00398892

Intervention type: DRUG
Group type: OTHER
Intervention: Lipoic acid
Description: Lipoic acid capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Lipoic acid
Description: Lipoic acid capsules
Study: NCT03206853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid Operating Techniques
Description: It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hybrid Operating Techniques
Description: It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
Study: NCT04058145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: AMD3100 is a drug that inhibits a chemokine CXCR4 which promotes cancer cell growth, spread, and survival and controls immune cell trafficking. Inhibiting CXCR4 expels the immune-suppressive cells out of the tumor and attract the cancer-killing immune cells into the tumor environment so that the body's immune system may be able to better attack the cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor.
Study: NCT02302781

Intervention type: OTHER
Intervention: Questionnaires
Description: Several validated questionnaires, depending on moment in fertility work up or treatment.
Study: NCT01410409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Burana
Description: 400 mg x 3/day for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Burana
Description: 400 mg x 3/day for three weeks
Study: NCT04298554

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBD Oil
Description: CBD PURE CBD OIL 20mg/1ml concentration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hemp Oil
Description: CBD PURE HEMP OIL
Study: NCT04635215

Intervention type: DEVICE
Intervention: Sensura Mio Bodyfit technology ostomy pouches
Description: The use of medical devices, the ostomy pouches from Sensura Mio Bodyfit technology range, will be studied from inclusion visit (less than one month after the beginning of use) and during 3 months.
Study: NCT02118389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucerna
Description: Glucerna 52g meal replacement
Study: NCT04430543

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: CBM sessions are computer tasks that take 15 minutes each. CBM is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. CBM will involve pushing 90% of alcohol stimuli (pulling 10%) and pulling 90% of neutral stimuli (pushing 10%).

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Training
Description: Sham training sessions are computer tasks that take 15 minutes each. Sham training is similar to an alcohol approach avoidance task (AAT) in that they will involve moving their mouse forward to simulate an avoidance/push response and backward to simulate an approach/pull response in response to alcohol and neutral stimuli depending on photograph orientation. Photos will get larger as if coming toward the participant when pulled and will get smaller as if moving away when pushed. Sham training will involve pushing and pulling 50% of each type of stimuli (alcohol and neutral)
Study: NCT01410409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazol
Description: 20mg x 1/day for three weeks
Study: NCT03378362

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial denervation of the wrist joint
Description: Partial denervation of the wrist (posterior and anterior interosseous neurectomy) through a single dorsal approach.
Study: NCT03934931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streamlined weekly DOT visits
Description: Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streamlined weekly DOT visits
Description: Streamlined, weekly DOT clinic visits to have health worker observe medication ingestion and screen for side effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly DOT visit reminders
Description: Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly DOT visit reminders
Description: Weekly SMS or interactive voice response (IVR) phone call reminder for DOT clinic visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost reimbursement DOT
Description: Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost reimbursement DOT
Description: Reimbursement of costs associated with weekly clinic visits (15,000 Ush/visit in Weeks 2-12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99DOTS
Description: 99DOTS-based digital adherence technology to monitor and promote adherence
Study: NCT01410409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazol
Description: 20mg x 1/day for three weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazol
Description: 20mg x 1/day for three weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
Study: NCT03934931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 99DOTS
Description: 99DOTS-based digital adherence technology to monitor and promote adherence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly SAT dosing reminders/check-ins
Description: Weekly SMS or IVR phone call dosing reminder/check-in for side effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly SAT dosing reminders/check-ins
Description: Weekly SMS or IVR phone call dosing reminder/check-in for side effects

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost reimbursement SAT
Description: Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost reimbursement SAT
Description: Reimbursement of costs associated with streamlined refill and end-of treatment clinic visits (15,000 Ush/visit in Weeks 6 and 12)
Study: NCT01410409

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: For participants with a BMI equal to or \>25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
Study: NCT01149824

Intervention type: DRUG
Group type: OTHER
Intervention: Salvinorin A

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT01493570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet
Study: NCT01410409

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden.
Study: NCT01493570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 409306
Description: Film-coated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study: NCT00925912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal block
Description: 0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
Study: NCT01410409

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient education
Description: The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR
Description: Surgical treatment with insertion of total knee replacement following standard procedures.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKR
Description: Surgical treatment with insertion of total knee replacement following standard procedures.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insoles
Description: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insoles
Description: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insoles
Description: The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).~The participants will be advised to use the insoles in all shoes.
Study: NCT01809457

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational poster
Description: educational poster for dental trauma
Study: NCT03940339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital myofascial release
Description: The MFR technique will be given in the upper cervical region with the patient in supine position. The MFR will be given for three repetitions per session, three times per week for the period of four weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physiotherapy
Description: The control group will be receiving conventional physiotherapy treatment for hamstring tightness which includes static stretching, modified hold-relax stretching and contract relax technique.
Study: NCT04243200

Intervention type: OTHER
Intervention: Hypos can strike twice
Description: The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover.

Intervention type: OTHER
Intervention: Hypos can strike twice
Description: The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover.

Intervention type: OTHER
Intervention: Hypos can strike twice
Description: The Hypos can strike twice intervention involves ambulance staff providing treatment to patients experiencing hypos and advising them to access follow-up care by their GP/specialist diabetes team. This is backed up by giving patients a Hypos can strike twice information booklet which they can read when they recover.
Study: NCT03418922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Specified doses will be administered orally on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Specified doses will be administered orally on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified doses will be administered intravenously on specified days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified doses will be administered intravenously on specified days.
Study: NCT03438409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic gait training
Description: Robotic gait training
Study: NCT01026805

Intervention type: DEVICE
Intervention: Interlace Medical 1st Generation Hysteroscopic Morcellator
Description: The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
Study: NCT03387540

Intervention type: DRUG
Intervention: ICI
Description: Immune checkpoint inhibitor targeting either PD-1, PD-L1 or CTLA-4, and included in the following list (ATC classification): Ipilimumab (L01XC11), Nivolumab (L01XC17), Pembrolizumab (L01XC18), Durvalumab (L01XC28), Avelumab (L01XC31), Atezolizumab (L01XC32).
Study: NCT02797132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LUM/IVA
Study: NCT05168397

Intervention type: OTHER
Intervention: RV4857A
Description: RV4857A formula CD2110 is a sunscreen product